Investors with a lot of money to spend have taken a bearish stance on CRISPR Therapeutics (NASDAQ:CRSP). And retail traders should know. We noticed this today when the trades showed up on publicly ...

John Greene, a director at $CRSP, bought 7,000 shares of the company on 02-26-2025 for an estimated $313,947. This trade was reported by Quiver Quantitative using ...

Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and a rating upgrade by a Wall Street analyst. Alongside earnings results ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $40.49 ... and the technology-centric Nasdaq increased by 1.35%. Prior to today's trading, shares of the company had lost ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session ... At the same time, the Dow added 0.38%, and the tech-heavy Nasdaq gained 0.98%. The company's shares have seen an increase of ...

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the trading session's close. They were highly encouraged by the specialized ...

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to earnings of $1.10 per share a year ago.

In trading on Friday, shares of CRISPR Therapeutics AG (Symbol: CRSP) crossed above their 200 day moving average of $49.55, changing hands as high as $52.60 per share. CRISPR Therapeutics AG ...